No connection

Search Results

FMS vs IONS

FMS
Fresenius Medical Care AG
BULLISH
Price
$22.77
Market Cap
$12.44B
Sector
Healthcare
AI Confidence
75%
IONS
Ionis Pharmaceuticals, Inc.
BEARISH
Price
$75.17
Market Cap
$12.42B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
FMS
11.56
IONS
--
Forward P/E
FMS
5.62
IONS
-120.83
P/B Ratio
FMS
0.81
IONS
25.1
P/S Ratio
FMS
0.63
IONS
13.16
EV/EBITDA
FMS
6.25
IONS
-33.45

Profitability

Gross Margin
FMS
25.62%
IONS
1.29%
Operating Margin
FMS
11.68%
IONS
-105.47%
Profit Margin
FMS
4.98%
IONS
-40.41%
ROE
FMS
7.93%
IONS
-70.8%
ROA
FMS
3.62%
IONS
-7.31%

Growth

Revenue Growth
FMS
-0.3%
IONS
-10.3%
Earnings Growth
FMS
420.0%
IONS
--

Financial Health

Debt/Equity
FMS
0.76
IONS
5.35
Current Ratio
FMS
1.26
IONS
3.83
Quick Ratio
FMS
0.85
IONS
3.51

Dividends

Dividend Yield
FMS
3.58%
IONS
--
Payout Ratio
FMS
42.76%
IONS
0.0%

AI Verdict

FMS BULLISH

FMS presents a classic deep-value opportunity, characterized by a stable Piotroski F-Score of 6/9 and a current price ($22.77) trading significantly below both its Graham Number ($35.27) and Intrinsic Value ($58.12). While top-line revenue growth is stagnant (-0.30%), the company has demonstrated a massive recovery in earnings and maintains a sustainable dividend payout ratio of 42.76%. The valuation is exceptionally attractive with a Forward P/E of 5.62 and a Price/Book of 0.81. However, the bullish value thesis is countered by a completely bearish technical trend and weak insider sentiment, suggesting a 'value trap' risk if revenue does not stabilize.

Strengths
Significant undervaluation relative to Graham Number and Intrinsic Value
Strong earnings recovery with YoY growth of 420%
Attractive valuation multiples (P/B 0.81, P/S 0.63, Forward P/E 5.62)
Risks
Stagnant revenue growth (-0.30% YoY) indicating a lack of top-line momentum
Severe bearish technical trend (0/100 score)
Low insider sentiment (40/100) suggesting lack of internal confidence
IONS BEARISH

IONS presents a significant disconnect between its market valuation and fundamental performance. While the Piotroski F-Score of 5/9 indicates stable financial health, the company is grappling with negative revenue growth (-10.30%) and a severe collapse in YoY EPS (-167.4%). Despite a massive 181% price surge over the last year, the valuation is extreme with a Price/Book of 25.10 and a Price/Sales of 13.16. Heavy insider selling by the CEO and CFO, combined with a bearish technical trend, suggests the current price is driven by speculative pipeline expectations rather than realized value.

Strengths
Strong short-term liquidity with a Current Ratio of 3.83
Consistent history of beating earnings estimates (3 of last 4 quarters)
Strong analyst consensus with a target price of $97.60
Risks
Extreme valuation premiums (P/B 25.10, P/S 13.16)
Negative revenue growth (-10.30% YoY) and declining Q/Q revenue
Severe profitability issues with an operating margin of -105.47%

Compare Another Pair

FMS vs IONS: Head-to-Head Comparison

This page compares Fresenius Medical Care AG (FMS) and Ionis Pharmaceuticals, Inc. (IONS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile